IndraLab

Statements

USP33 binds FGFR2. 6 / 6
| 6
sparser
"Before starting pemigatinib, her plasma cfDNA FGFR2-USP33 fusion was detected at 1.1% VAF and subsequently decreased to an undetectable level two weeks after starting treatment (Fig. xref )."
39289482
sparser
"In the FIGHT-101 trial, a patient with KRAS WT PDAC harboring an FGFR2-USP33 fusion achieved a partial response to pemigatinib that was maintained for 10.7 months before disease progression [ xref ]."
36551707
sparser
"In the FIGHT-101 clinical trial, one of five patients with pancreatic cancer showed a partial response to anti-FGFR1-3 treatment (pemigatinib); this case was positive for FGFR2::USP33 fusion [ xref ]."
38542259
sparser
"C382R mutation, and FGF3,4,19 amplifications), and 1 each with gallbladder cancer ( FGFR2-BICC1 fusion), pancreatic cancer ( FGFR2-USP33 fusion), urothelial cancer ( FGFR3 p."
35176457
sparser
"Following disease progression on this trial, genomic testing revealed an FGFR2-USP33 fusion, and she subsequently started a basket trial for the FGFR-selective inhibitor pemigatinib where she exhibited a partial response with a 43% reduction in tumor size (NCT02393248) and remained on therapy for 28 months (Fig. xref , Supplementary Figs. xref , xref , xref ) xref ."
39289482
sparser
"One in four patients with pancreatic cancer had FGFR2-USP33 fusion and maintained a response for 10.7 months."
37893023